Publication
Prevalence of BRCA1/2 variants in an Ovarian Cancer Cohort: outcomes from a Nationwide Testing Program.
Ciara S McNevin, Kate Murphy, Pierre Murchan, Andrea Hennessy, Orla Fitzpatrick, Sharon O'Toole, Paul Smyth, Emer Atkinson, Georgia Thodi, Anne-Marie Baird, Steven G Gray, Cathal O'Brien, Trudi McDevitt, Roshni Deepa Kalachand, Brendan Doyle, Niamh Coleman, Stephen P Finn, Karen A Cadoo
- Source
- PubMed
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260911-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the management of BRCA1- and BRCA2-associated ovarian cancer (OC). In 2020, Ireland implemented a nationwide, oncology-led pathway for mainstreamed BRCA1/2 testing in patients with OC. This study evaluated the pathway and…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available